Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monoferric for Prenatal Iron Deficiency
NCT05763043Phase 1Recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2024
- Primary completion
- Oct 2028
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA), sponsored by Oregon Health & Science University. Primary endpoint: Proportion of participants who experienced a resolution of iron deficiency anemia. Started Jan 2024; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05763043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763043.